



**Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Lilly USA, LLC (Lilly)**

**Announcement of Interest to Receive Independent Medical Education (IME) Grant Applications**

On January 11, 2011 Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Lilly USA, LLC (Lilly) announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds. We are committed to supporting education that fosters innovative, high quality, independent medical education for healthcare professionals and patients that narrows unmet medical needs, maintains clinical excellence, and aims to improve patient health outcomes in areas of interest to the BIPI and Lilly Diabetes Alliance.

Under the terms of the BIPI and Lilly Diabetes Alliance, educational grants are received, processed, and paid by Boehringer Ingelheim Pharmaceuticals. Funding for educational grants is derived from both organizations.

**The intent of this Request for Educational Grant Applications (REGA) announcement is to notify experienced and eligible medical education providers that BIPI and Lilly are interested in receiving applications for IME activities pertinent to diabetes and aligned to the specifications outlined below.**

Such IME must be based on identified education needs of healthcare provider-learners, be evidence-based in the aim to improve the care of patients, and may or may not offer continuing education (CE) credit. Importantly BIPI and Lilly-supported IME will adhere to relevant regulatory guidance and industry standards.

Grant applications must be submitted online at [www.bipi-lilly-grants.com](http://www.bipi-lilly-grants.com) and once received BIPI and Lilly will carefully consider each request with a goal to provide a decision less than 60 days from receipt. The outcome of each review may result in full or partial funding of the requested amount, or in a denial decision.

Unless otherwise noted on [www.bipi-lilly-grants.com](http://www.bipi-lilly-grants.com), during the period of this REGA and throughout the year BIPI will also accept requests from eligible organizations that are not in response to a REGA. Should those grant applications be received during the time of this REGA and also align with the parameters outlined in this announcement, BIPI and Lilly will review those applications and evaluate them according to the same quality and eligibility standards.

If you have questions about the REGA application process, please contact the Boehringer Ingelheim Pharmaceuticals Medical Education and Research Grants Office at 1-800-295-0717.

## Request for Educational Grant Applications December 2018 Metabolics Diabetes

REGA (Request for Educational Grant Applications) Posting Date	Dec 27 <sup>th</sup> , 2018
REGA Submission Deadline	Accepted on an <b>ongoing</b> basis until <b>February 6<sup>th</sup>, 2019</b> .
Therapeutic Area	Metabolics
Disease	<b>Diabetes</b>
Educational Focus <i>(Educational activities should address one or more of the following educational gaps):</i>	<ul style="list-style-type: none"> <li>• Improve clinicians' understanding of the current guidelines and scientific evidence supporting management of cardiovascular risk in patients with Type 2 diabetes</li> <li>• Improve clinicians' understanding and knowledge of optimally managed benefit/risk profiles of treatments for patients with Type 1 Diabetes.</li> <li>• Enhance clinicians' awareness and knowledge of emerging scientific evidence regarding treatment of patients with type 2 diabetes patients with or without concomitant heart failure or renal disease</li> </ul>
Audience/Learners	Endocrinologists, Cardiologists, Primary Care Physicians, Hospitalists, Emergency Room Physicians, Physician Assistants, Nurse Practitioners, Pharmacists, Certified Diabetes Educators, Managed Care HCPs, and other HCPs who care for patients with diabetes.
Educational Format(s)	<p>Programs occurring in 2<sup>nd</sup>/3<sup>rd</sup>/4<sup>th</sup> quarters of 2019 in the following format(s) will be considered:</p> <ul style="list-style-type: none"> <li>• National live meetings, national congresses/medical association meetings (e.g., American Association of Nurse Practitioners, American Association of Physician Assistants, American Diabetes Association, American Academy of Family Physicians, Heart Failure Society of America, American College Emergency Physicians)</li> <li>• Local/regional live, grand rounds, web-based, and print-based</li> </ul>
Available Support	<b>Please note that BIPI and Lilly encourage submission of grant applications with multiple sources of funding support.</b>
Selection Criteria	<p>Applications will be evaluated based upon:</p> <ul style="list-style-type: none"> <li>• Knowledge of and experience within the therapeutic area and disease state</li> <li>• Well defined and researched needs assessments that identify current practice gaps of identified learners</li> <li>• Linkage of educational needs to achievable learning objectives</li> <li>• Incorporation of adult learning principles into the educational design</li> <li>• Rigorous mechanisms in place to validate content and resolve identified conflicts of interest</li> <li>• Outcomes measures that demonstrate achievement of learning objectives</li> </ul>
Outcomes Measures	<p>Moore's Level 4 outcomes or higher are expected.</p> <p>Moore DE Jr, Green JS, Gallis HA. <i>Achieving desired results and improved outcomes: integrating planning and assessment throughout learning activities.</i> <u>J Contin Educ Health Prof.</u> 2009 Winter; 29 (1):1-15.</p>

### BIPI Standards for IME Applications:

Submission requirements are posted at [http:// www.bipi-lilly-grants.com](http://www.bipi-lilly-grants.com)

## Request for Educational Grant Applications December 2018 Metabolics Diabetes

---

1. This REGA does not commit BIPI or its alliance partners to award a grant of any particular size nor to pay any costs incurred in the preparation of a response to this request.
2. All communications about the REGA must come exclusively to the BIPI Medical Education and Research Grants Office. Applications received through other channels will not be considered.
3. BIPI adheres to both Federal and State Transparency Reporting Regulations and as such will report transfers of value from education grants provided to Health Care Providers and medical, scientific, and patient organizations as defined on [www.bipigrants.com](http://www.bipigrants.com) in the document "Medical Education Grants Sunshine Reporting Requirements".
4. Grant funding shall be paid directly only to the entity that is specified in the grant application as "applicant". BIPI will not make any payments to any individuals or co-sponsors of the educational program.
5. All applications must have comprehensive and itemized budgets.
6. Grantees must reconcile expenses and provide an outcomes report upon completion of the BIPI-supported educational program.